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1. Introduction 
The physiologic roles of both follicle stimulating hormone and luteinizing hormone are well 
established in the natural menstrual cycle. Research by Ryan and colleges in the 1960s 
established the concept of two different cells in the ovarian follicle, the thecal and granulosa 
cells, functioning in different manners to produce products of the steroid pathway, the “two 
cell hypothesis” (1, 2). Further work over the next two decades established the “two-cell 
two-gonadotropin” theory, demonstrating the action of FSH on granulosa cells and LH on 
thecal cells (3). Thecal cells alone were shown to express CYP17, the gene encoding for the 
critical enzyme in the conversion of progesterone and pregnenalone to androgens (3). 
Conversely, granulosa cells were demonstrated to be the cell expressing aromatase, allowing 
for the conversion of the androgens derived from the thecal cells to be converted to 
estrogens. The cooperation of both cells under the influence of both gonadotropins is 
essential for normal folliculogenesis and steroidogenesis in the ovary. 
LH has several physiologic roles within the ovary in addition to its roll in androgen 
production (Figure 1). LH receptor activation leads to increases in adenylate cyclase and 
cAMP, resulting in increased mitochondrial transport of cholesterol necessary for 
steroidogeneis through upregulation of StAR (4, 5). LH activity also induces the expression 
of EGF-like growth factors amphiregulin and epiregulin from luteinized granulosa cells (6). 
These factors protect these cells from apoptosis, induce pro-survival signaling cascades, and 
are critical in peri-ovulatory events (6, 7). The mid-cycle LH surge causes a cascade of events 
leading to ovulation of the oocyte from the ovarian follicle and take the oocyte out of meiotic 
arrest (8). Finally, LH receptors have been demonstrated in the endometrium during the 
implantation window, raising a possible roll for LH in peri-implantation endometrial events 
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(9, 10). The specific importance of LH activity can be demonstrated in patients with LHβ or 
LH receptor gene mutations. Case reports of these male and female patients have 
demonstrated hypogonadism, infertility, pseudohermaphroditism, and amenorrhea (11-13).  
 
Figure 1. Key actions of LH within the ovary on the thecal cells, oocyte, and granulosa cells. Actions 
mediated by LH are indicated in red. 
In assisted reproduction technologies (ART), the importance of LH is demonstrated clearly 
in hypogonadotropic hypogonadic patients. Patients with a profound lack of endogenous 
LH fail to undergo complete follicular maturation in the absence of exogenous LH (14, 15). 
Such patients require the exogenous administration of both LH and FSH to optimize 
reproductive outcomes (4, 16, 17). Urinary human menopausal gonadotropins were initially 
utilized in assisted reproductive technologies. These preparations were islolated and 
purified from large pools of human urine. One of the early urinary hMG products was 
Pergonal 75. One ampule of Pergonal 75 contained 75 international units (IU) of FSH and 75 
IU of LH, which became an industry standard for ampules (18). These urinary hMG 
preparations contained both FSH and LH, as well as some hCG, and therefore patients were 
stimulated with both gonadotropins. Later advancements in monoclonal antibody 
technology enabled the production of urinary purified FSH and a more purified hMG, 
which is still used today (19, 20). Recombinant DNA technology using a mammalian cell 
culture system (Chinese hamster ovary cells) was used to produce recombinant human FSH, 
which was first licensed in 1995, and quickly replaced urinary FSH products. Recombinant 
human LH was later produced (18).  
Despite the clear biologic importance of LH outlined in the preceding paragraphs, 
numerous studies have demonstrated successful ART outcomes with the use of exogenous 
FSH only (21, 22). A likely explanation is that LH is a very potent hormone, activating the 
LH receptor for adequate ovarian steroidogenesis when only 1% of LH receptors are bound 
(23). Even after GnRH agonist or antagonist down-regulation, a majority of patients will 
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have LH levels > 1 IU/L, a level presumably capable of driving adequate steroidogenesis 
(21). While the majority of patients have adequate endogenous LH levels to have successful 
ART cycles without exogenous LH, the value of additional exogenous LH administration 
has been a matter of debate. This chapter will review the scientific evidence surrounding the 
administration of exogenous LH in various forms (rLH, hMG, hCG) and its affect on ART 
outcomes. 
2. Potential mechanisms of exogenous LH benefit in ART 
There are theoretical benefits of the use of exogenous LH for the oocyte and the 
endometrium. The putative purpose of controlled ovarian stimulation in ART is to 
maximize the number of oocytes retrieved. However, the evidence is clear that the addition 
of LH is not associated with an increase in the number of oocytes or the number of mature 
metaphase II oocytes (MII) retrieved. Indeed, the use of hMG has been shown to decrease 
the number of follicles, oocytes, and metaphase II oocytes (MII) as compared to rFSH alone 
(21, 22, 24-28), presumably due to the action of LH contained in hMG. This is confirmed by 
similar data comparing rLH plus rFSH versus rFSH alone which has shown a decrease in 
developing follicles and oocytes retrieved with rLH (29, 30). In the majority of these trials, 
the decrease was in oocytes from small to intermediate follicles, and the number of oocytes 
retrieved from large follicles and the number of MIIs retrieved were not different. This 
suggests the possibility that the use of exogenous LH activity is associated with a decreased 
in the development of small follicles which may have been unlikely to yield a fertilized 2PN. 
There appears to be no negative effect on the development of larger follicles.  
In a series of in vivo studies evaluating the effect of LH activity on follicle growth, Filicori 
and colleges confirmed the findings that LH activity can decrease the growth of small 
follicles without impacting the continued growth and maturity of larger follicles. First, they 
demonstrated that the number of follicles under 10mm in size during ART stimulation 
positively correlated with FSH dose (r=0.193, p<0.05) but negatively correlated to LH dose 
(r=0.648, p<0.0001) (31). In another study, it was demonstrated that incrementally decreasing 
the dose of FSH from day 7 of stimulation and increasing the dose of LH resulted in a 
decrease in the number of follicles <10mm in size, without affecting follicles over 14mm in 
size (32). To evaluate if this effect was due to the decreasing FSH dose or the increasing LH 
dose, they performed a similar experiment where FSH was held steady at 150IU per day and 
patients were placed into groups of incrementally increasing LH doses. In this experiment, 
increasing doses of LH (in the presence of a constant dose of FSH) was again associated with 
a decrease in number of small follicles while not affecting the larger follicles (33). When the 
experiments were repeated utilizing hMG, hMG was also associated with a decrease in 
small follicles (34). These experiments and the results of many randomized controlled trials 
demonstrate that any beneficial effect of LH activity is not the result of an increase in oocyte 
yield.  
While the number of total oocytes, especially from small follicles, appears to be diminished 
in ART cycles utilizing LH, the quality of those oocytes may be increased. While direct 
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measures of oocyte quality are difficult to assess clinically, some studies have noted an 
increased fertilization rate in oocytes obtained from cycles stimulated with LH (24, 30). 
Numerous trials have also demonstrated that the addition of LH activity results in an 
increase in serum estradiol on the day of hCG (Figure 2), which may represent a higher 
quality cohort of developing follicles (22, 26, 30, 35-43). LH supplementation was 
demonstrated to result in lower levels of apoptosis in cumulous cells as compared to FSH 
stimulation only (44). Cumulous cell apoptosis has been used a marker of oocyte quality and 
the decrease in apoptosis with the addition of LH is consistent with its post-receptor effects 
through increased epiregulin and amphiregulin.  
 
Figure 2. Randomized controlled trials demonstrating an increased estradiol level on the day of hCG 
with rLH (top) or hMG (bottom) as compared to rFSH alone (adapted from Hill et al., 2012 (21)). 
Another possible effect of LH is on the endometrium and embryo implantation. LH 
receptors are present in the endometrium during the window of implantation (9, 10), but 
whether these receptors play a direct role in embryo implantation needs further 
investigation. An indirect effect on the endometrium has been proposed via decreased 
premature progesterone secretion (24, 45). There is a growing body of evidence to suggest 
that prematurely elevated progesterone levels on the day of hCG have a negative impact on 
embryo implantation without affecting embryo quality (46-51). The evidence that this is an 
endometrial effect is supported by studies in oocyte donor cycles, where elevation of 
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progesterone in the donor is not associated with decreased implantation in the recipient (52). 
Progesterone is necessary for endometrial development and embryo implantation. 
However, premature rises in progesterone can advance the development of the 
endometrium and lead to asynchrony with the embryo development (46, 51, 53). FSH drives 
the conversion of cholesterol to progesterone but lacks CYP17 to further convert 
progesterone to androgens (54, 55). LH stimulates CYP17 in thecal cells to further convert 
the progesterone to androgens, which are subsequently aromatized in the granulosa cell (3). 
Under the two-cell two gonadotropin model, LH is protective of premature progesterone 
elevations prior to luteinization (24, 45) (Figure 3). Further investigation is needed to 
determine if exogenous LH administration is protective for the endometrium. 
 
 
Figure 3. Model demonstrating a possible mechanism by which the administration of exogenous LH 
decreases premature rises in serum progesterone. FSH stimulates granulosa cells to convert cholesterol 
to progesterone. Lacking CYP17, the granulosa cells cannot convert progesterone to androgens and thus 
progesterone is secreted from the cells. In the absence of adequate LH levels, this progesterone is 
secreted into the circulation where it can advance the endometrium prematurely. In the presence of 
adequate LH levels, the progesterone is converted into androgens by CYP17 in the thecal cells. The 
androgens are then taken up by the granulosa cells and converted to estrogens. In this model exogenous 
LH protects the endometrium from exposure to premature progesterone rises. Green arrows represent 
increased action. Red arrows represent decreased action.  
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There is evidence to suggest that suppressed LH levels in women during ART stimulation 
can have negative effects (Figure 4). Depending on the study, adverse outcomes have been 
demonstrated with LH below 0.5-1.2 IU/L. LH levels < 1.2 IU/L have been reported to be 
associated with decreased serum estradiol, poor follicular development, decreased oocyte 
yield, decreased high quality embryos, and lower pregnancy rates (14, 15). Below LH levels 
of 1IU/L, other researchers demonstrated slower follicular growth and decreased estradiol 
(56). Finally, LH levels < 0.5 IU/L have been associated with increased pregnancy loss, lower 
implantation rates, and lower live birth rates (57, 58).  
 
Figure 4. Demonstrates the concept of an LH window. Low LH levels have been associated with 
decreased poor pregnancy outcomes with levels below 0.5-1.2 IU/L, demonstrating a threshold below 
which low LH causes poor outcomes. High LH levels have also been associated with poor pregnancy 
outcomes with levels over 6.8-10 IU/L. This gives rise to the concept of a therapeutic LH window (in 
green) to maximize ART outcomes. 
It has also been demonstrated that elevated LH levels are associated with negative ART 
cycle outcomes. Decreased pregnancy rates and increased spontaneous abortion were 
reported with LH levels above 10 IU/L (59). Increased follicular arrest, decreased 
fertilization, higher recurrent pregnancy loss, and lower implantation rates have all been 
reported in patients with higher LH levels that controls, although ceiling values were not 
established in these studies (56, 60-63). This evidence that too much or too little LH activity 
can have negative outcomes has led to the concept of an LH window (4, 61, 64). In reality, 
10 
 
 
 
9 
 
 
 
8 
 
 
 
7 
 
 
 
6 
 
 
 
5 
 
 
 
4 
 
 
 
3 
 
 
 
2 
 
 
 
1 
 
 
0 
LH (IU/L) 
LH Threshold 
LH Ceiling 
LH Window 
Westergaard et al. 2000-  Increased pregnancy loss with LH <0.5 
Propst et al. 2011- Decreased implantation and live birth with LH <0.5  
Fleming et al. 1996- Decreased E2 and slower follicular growth LH <1 
Odea et al.,2008 Decreased E2, no follicles, no pregnancies with LH <1.2 
 
Lahound et al. 2006-  Decreased E2, decreased oocytes, fewer good embryos with LH <1.2 
Watson et al.1993-  recurrent pregnancy loss group had higher endogenous LH levels of 4.8 
Kolibianakis et al. 2003- Lower implantation rates and higher LH levels in fixed antagonist group 
Regan et al. 1990- Lower PR and increased SAB with LH >10 
Stranger et al. 1985- Decreased fertilization rate when LH levels >1 SD above the mean 
Loumaye et al. 2003-  Follicular arrest with LH of 6.8 
 
The Use of rLH, HMG and hCG in Controlled Ovarian Stimulation for Assisted Reproductive Technologies 59 
with GnRH analogues, most patients are not in danger of having elevated endogenous LH 
levels. Indeed, by day 6 of GnRH antagonist administration, endogenous LH levels are 
depressed to a mean level of 1.6 IU/L, a value much closer to the LH threshold than the 
ceiling (65). Similarly, long agonist protocols also suppress endogenous LH levels to a mean 
near 1 IU/L (66). The evidence would suggest the clinician should be more concerned with 
replacing an adequate LH level in patients under pituitary down-regulation and the threat 
of high LH levels is less prevalent. 
2.1. Summary points 
1. LH activity causes atresia of small follicles during ART stimulation 
2. Indirect evidence suggests increased oocyte quality with LH 
3. LH activity decreases oocyte yield due to a loss of these small follicle 
4. LH activity increases estradiol production from follicles  
5. LH activity may protect the patient from premature progesterone elevations 
3. Human menopausal gonadotropin 
hMG is a urinary gonadotropin preparation consisting equal activity of both LH and FSH 
and some hCG. It is available in highly purified forms, minimizing earlier preparation 
disadvantages of protein contamination leading to the risk of allergic reactions. Evaluating 
studies with hMG have the advantage of homogeneity. Due to the nature of hMG containing 
equal FSH and LH activity, all patients in the hMG group receive equal amounts of LH and 
FSH activity and start LH activity on the same day as the FSH activity is started. As hMG 
has been available for longer than rFSH, there are more studies and total data available for 
analysis.  
When looking at intermediate outcomes and surrogate markers for ART, hMG has not been 
demonstrably different than rFSH for ovarian stimulation. The results are similar in the 
proportion of MII oocytes, the number of high quality embryos, zona pellucida morphology, 
and polar body evaluation (42, 67-69). Studies have also shown no benefit in the number of 
oocytes retrieved with hMG and indeed numerous studies have shown a small decrease in 
the number of oocytes retrieved (typically around 1 oocyte less per retrieval) (22, 25-28, 41, 
67). In the majority of studies, the decrease in oocytes did not translate into a decrease in the 
number of MIIs retrieved per cycle, indicating the loss was in smaller, immature oocytes. 
hMG administration has been associated with higher serum and follicular fluids androgens 
and estrogens and lower serum progesterone levels on the day of hCG (22, 25, 41-43, 56, 70-
72). It has been proposed that this more favorable endocrine milieu reflects a healthier 
cohort of developing follicles in hMG cycles. One study also demonstrated increasing 
implantation rates with increasing doses of LH supplementation (73). This dose dependent 
benefit of LH could be due to an increase in the quality of the oocytes retrieved or due to an 
endometrial effect on implantation. However, this study was small and we are not aware 
that the findings have been confirmed.  
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There is a large body of randomized controlled trials available for analysis comparing hMG 
to rFSH only. These trials are relatively homogenous, with similar dosing strategies and 
primarily GnRH agonist pituitary downregulation. These RCT have been systematically 
evaluated in several meta-analyses shown in Table 1 (74-78). The number of patients 
required to show a benefit in hMG had been calculated at over 2100 (76). This is 
demonstrated in a 2005 meta-analysis by Al-Inany et al. where 8 RCTs including 2031 ART 
cycles failed to show a statistically significant improvement in live birth (OR 1.18, 95%CI 
0.93-1.50) although a trend to benefit may have been seen (76). When the same authors 
repeated a meta-analysis in 2008, there were 11 RCTs including over 2900 patients available 
for analysis (75). This time a significant improvement in live birth (OR 1.20, 95%CI 1.01-1.42) 
was demonstrated with the use of hMG versus rFSH alone (75). This data was confirmed in 
a separate meta-analysis by Coomarasamy et al. showing an improvement in live birth with 
hMG (OR 1.18, 95%CI 1.02-1.38) (77). Two more recent meta-analyses in 2010 each failed to 
show a significant improvement in live birth with the use of hMG (74, 78). However, the p 
values for these studies were borderline significant (0.051-0.06) and the odds ratio of 
pregnancy was similar to the other trials. Indeed, the last four meta-analyses had all 
demonstrated between a 3-4% absolute increase in pregnancy and a 10-21% relative increase 
in pregnancy with the use of hMG as compared to rFSH alone. These numbers translate to a 
NNT of approximately 32 patients with hMG to achieve one additional live birth. The 
clinical relevance of this number has been a matter of debate, but there is a clear statistical 
benefit to utilizing hMG. The majority of these source RCTs for these meta-analysis were 
from cycles utilizing a GnRH agonist protocols.  
 
Author, Year RTCs Number 
of 
Patients 
Absolute 
Pregnancy 
Benefit 
Relative 
Pregnancy 
Benefit 
Pregnancy OR 
(95% CI) 
Al-Inany, 2005 8 2031 - - 1.18 (0.93-1.50) 
Al-Inany, 2008 11 2937 +3% +21% 1.20 (1.01-1.42) 
Coomarasamy, 2008 7 2159 +4% +18% 1.18 (1.02-1.38) 
Jee, 2010 5 2299 +3% +12% 1.14 (0.98-1.33) 
Lehert, 2010 16 3952 +3% +10% 1.10 (0.97-1.25) 
Table 1. Recent meta-analysis comparing hMG versus rFSH for ovarian stimulation in ART cycles. 
A recent RCT published in 2012 has provided similar evidence for the benefit of hMG in 
GnRH antagonist cycles. Devroey et al. randomized 749 patients to receive either hMG or 
rFSH (79). There were numerous strengths to this trial: rigorously described randomization, 
allocation and concealment, the use of 25 clinics in 7 countries, all patients were only 
allowed a single blastocyst transfer, and the follow-up included live births from the fresh 
cycle plus subsequent frozen cycles of embryos obtained during the study. Patients in the 
hMG arm had higher estradiol, LH, and FSH measured in the serum on the day of hCG. 
There was a significant reduction in the number of oocytes retrieved in the hMG group (-1.6 
oocytes per retrieval). Importantly, an absolute difference of +3% in live birth with the use of 
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hMG in the pre-protocol analysis and +2% in the intent-to-treat analysis, although the 
findings did not achieve statistical significance (79). The cumulative live birth rate (fresh and 
frozen cycles) was 40% in the hMG group and 38% in the rFSH group. This study was in 
agreement with a prior publication evaluating 280 patients using a GnRH antagonist 
protocol with hMG or rFSH, also showing a non-significant 3% improvement in live birth 
rate (22). While there is not enough data to definitively conclude that hMG is beneficial in 
GnRH antagonist cycles, the available data shows a similar improvement to that seen in 
GnRH agonist cycles. 
3.1. Summary points 
1. hMG is a urinary derived gonadotropin formulation containing equal amounts of LH 
and FSH activity 
2. hMG may decrease the number of oocyte retrieved by 1 oocyte per retrieval as 
compared to FSH 
3. hMG increases live birth by 3-4% as compared to rFSH in GnRH agonist cycles 
4. hMG may also increase live birth in GnRH antagonist cycles 
4. Recombinant luteinizing hormone 
The advent of recombinant DNA technology eventually led to the availability of 
recombinant LH in clinical practice (80). Urinary isolation of LH is an inefficient process, 
with 60-250 IU/mg of protein isolate (81). Conversely, recombinant LH contains 20,000 – 
30,000 IU/mg of protein (81). The pharmacodynamics of recombinant and urinary derived 
LH preparations show similar clearance, half-life, and concentration curves (16, 81). The 
pharmacodynamics profiles of rLH are similar whether it is administered subcutaneously or 
intramuscular and it does not impact the pharmacodynamics of co-administered rFSH (82-
84). In hypogonadotropic hypogonadal patients, a dose of 75IU of rLH has been 
demonstrated to promote adequate folliculogenesis when administered with FSH (85). rLH 
has potential advantages over the LH activity in hMG in that there is less risk of protein 
contamination and allergic reaction and it allows for the LH dose to be specifically adjusted 
without affecting the FSH dose. 
There are numerous RCT evaluating rLH plus rFSH versus rFSH alone, but the data is 
complicated by significant heterogeneity between the trials (29, 30, 36-41, 86-95). The fact 
that the rLH dose can be administered at a separate starting time and doses from the rFSH 
dose has allowed researchers and clinicians to be more varied in the approach to rLH 
administration as compared to hMG. While this has allowed for the investigation of 
interesting protocols, it makes interpretation and meta-analysis of the data more complex. 
rLH has been investigated as a priming agent started up to 7 day prior to rFSH 
administration, as an early follicular phase agent beginning on days 1-3 of rFSH, and as a 
late follicular agent starting day 5-8. The dosing of rLH has also varied from 75IU to 300IU 
per day or as a fixed ratio to the FSH dose. 
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Three RCT have shown higher implantation or pregnancy rates in women receiving rLH 
supplementation (24, 38, 94). Patients with an inadequate response to rFSH alone have also 
been shown to benefit from the addition of 150IU of rLH as compared to increasing the FSH 
dose by 150IU (39). However, the vast majority of RCT evaluating rLH have failed to show 
an improvement in clinical pregnancy when compared to rFSH alone (29, 30, 36, 37, 40, 41, 
86-89, 91, 92, 95). The majority of these trials were underpowered to detect for small 
differences in pregnancy outcomes between the study arms.  
Four meta-analyses have been done to compare the outcomes of RCTs evaluating the use of 
rLH in ovarian stimulation (96-99). Kolibianakis et al. demonstrated no difference in live 
birth with the use of rLH, including in sub-analysis of early and mid-follicular 
administration or GnRH antagonist and agonist administration (97). Baruffi et al. did 
demonstrated a higher serum estradiol on the day of hCG (+514 pg/ml) and a higher number 
of MII oocytes retrieved (+0.88) with the use or rLH, but these differences did not translate 
into improve clinical pregnancy (96). In the largest meta-analysis, Mochtar et al. 
demonstrated a trend towards improved live birth with rLH, but the result did not reach 
statistical significance (OR 1.22, 95%CI 0.95-1.56) (98). However, pooled analysis did show 
an improvement in live birth for poor responders who were stimulated with rLH (OR 1.85, 
95% CI1.10-3.11) (98). rLH was shown to have increased estradiol, fewer days of stimulation, 
and lower FSH administration in a fourth meta-analysis, although once again no 
improvement in pregnancy outcomes was demonstrated (99). 
 
Author, Year RTCs Number of 
Patients 
Pregnancy Odds Ratio (95% CI) 
Baruffi, 2007 5 434 0.89 (0.57-1.36) 
Kolibianakis, 2007 7 701 0.92 (0.65-1.31) 
Mochtar, 2007 14 2612 1.22 (0.95-1.56) 
Oliveira, 2007 5 1225 1.10 (0.85-1.42) 
Table 2. Meta-analyses comparing rLH plus rFSH versus rFSH only. 
The data from the RCT and meta-analyses evaluating rLH is similar to that of hMG in 
showing a reduction in the amount of FSH required for stimulation and an increase in 
serum estradiol. However, these data differ in that they do not show a convincing increase 
in pregnancy outcomes. It is possible that this is due to the smaller numbers in the rLH 
meta-analysis. Only the Mochtar et al. paper had a power similar to that of the hMG meta-
analysis to detect for live birth as an outcome. The heterogeneity within the design and 
results of the rLH studies themselves also is associated with a decreased power to detect for 
pregnancy outcomes and a wide confidence interval. It is also possible that the differences 
seen in the meta-analyses between rLH and hMG is not only statistical, but also due to the 
differences in the pharmaceuticals themselves. Differences in the glycosylation of LH 
between urinary and recombinant preparations and the addition of hCG to urinary 
preparations may lead to fundamental differences in biologic action which affect clinical 
results.  
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4.1. Summary points 
1. rLH increases serum estradiol 
2. rLH decreases the amount of rFSH needed for ovarian stimulation 
3. It is uncertain if the addition of rLH increases pregnancy outcomes in ART 
5. Human chorionic gonadotropin: 
hCG and LH have a significant degree of structural homology and both act on the LH 
receptor. hCG has a 6-8 fold affinity for the LH receptor as compared to LH only. 
Glycosylation additions to hCG also give it a longer half-life than LH. This has resulted in 
trials investigating the ability of hCG to replace LH for ovarian stimulation. 
Two studies have reported the use of hCG in the early follicular phase of ovarian 
stimulation (100, 101). These trials and two case reports have used various dosing strategies 
to deliver the hCG, including 200 IU per day for four or seven days, 50 IU per day for 14 
days, and 1,250 IU in a single dose on cycle day two (100-103).  
In one trial, the addition of hCG resulted in significantly greater highly quality embryos 
(85% versus 47%) and pregnancy rates (46% versus 31%) (100). Overall, there is a lack of 
randomized controlled data evaluating the use of hCG from the early follicular phase, but 
what data is available is promising. 
hCG has been evaluated as a mid-to-late cycle supplement to rFSH stimulation cycles in six 
trials. The dose of hCG utilized was 200IU per day in five trials and 250IU in another (104-
109). All trials were initiated with rFSH only for stimulation with hCG added when the 
follicles were between 12-14mm in size. Five of the trials reported a significantly higher 
estradiol level on the day of hCG in patients randomized to receive hCG stimulation, with 
increases in estradiol ranging from 700-1500 pg/ml (104-107, 109). A study by Filicori et al. 
further demonstrated a significantly higher fertilization rate in patients receiving hCG 
versus rFSH only (74% versus 48%) (104). The remainder of the trials did not show any 
differences in outcomes with hCG with regards to fertilization, implantation, or pregnancy 
(105-107, 109). These RCT total 614 patients and demonstrate that the addition of hCG 
results in higher estradiol levels and at least comparable ART outcomes to rFSH stimulation 
only. 
In a retrospective analysis, Van Horne et al. demonstrated that the addition of daily hCG 
(50-100 IU per day) to a rFSH only stimulation protocol resulted in a decrease in average 
FSH administration by 1000IU per patient and resulted in a cost savings of $600 in a 
military healthcare facility (110). In a subsequent publication, this same group 
demonstrated that low dose hCG was effective at significantly improving implantation 
rates (54% vs. 19%) and live-birth rates (64% vs. 25%) in patients who had endogenous LH 
levels ≤ 0.5 IU/L, while it had no benefit in patients with LH levels >0.5 IU/L (58). A meta-
analysis of over 1,000 patients has demonstrated that the addition of hCG to ovarian 
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stimulation results in a decreased requirement for rFSH, leading to a cost savings with 
comparable outcomes (108).  
A recent meta-analysis summarized the evidence on the use of hCG in ovarian stimulation 
(111). The analysis included 11 RCT and 1,068 ART cycles. While the conclusions were 
limited due to heterogeneity with the source studies, significant conclusions were reached. 
It was demonstrated that the total dose of FSH was decreased by over 800 IU in patients 
who were supplemented with hCG. The use of hCG resulted in a small decrease in the 
number of MII oocytes retrieved (WMD -0.30, 95%CI -0.44 to -.66) (111). This data is 
consistent with the effect of LH on follicular growth discussed earlier in the chapter and a 
reduction of 0.3 oocytes per patient may be of small clinical impact. In analysis of 3 of trials 
reporting on early follicular phase hCG administration, there was no demonstrable benefit 
in clinical pregnancy. However, analysis of five of the trials reporting on late follicular 
phase hCG demonstrated a significant benefit in clinical pregnancy (RR 1.32, 95%CI 1.06-
1.64).  
5.1. Summary points 
1. hCG can be used to provide LH action 
2. 50-200 IU per day is an appropriate hCG dose  
3. hCG supplementation decreases FSH requirement and ART cycle cost 
4. hCG supplementation when the lead follicle is 12-14mm improves clinical pregnancy 
6. Special patient groups 
The use of rLH has been evaluated specifically in patients of advanced reproductive age, 
defined as 35 years of age and older in most studies. Eight RCT trials have compared rLH 
with rFSH versus rFSH stimulation only in this patient population (24, 29, 41, 88, 91, 93, 94). 
None of the trials reported a significant difference in oocytes retrieved with rLH. One trial 
reported a significant decrease in MII oocytes retrieved (5.5 versus 6.9) per patient with the 
use of rLH (29). The majority of the trials were small and no differences in outcomes were 
demonstrated with the use of rLH. The largest trial published by Bosch et al. enrolled 720 
total patients (24). In patients 35 years old and younger, there was no benefit to rLH 
administration. However, in the advanced reproductive age group, there was a significantly 
increased fertilization rate (68% versus 61%) and implantation rate (26.7% versus 18.6%) 
with the use of rLH (24). There was a trend towards increased clinical pregnancy in the 
patients of advanced reproductive age who were supplemented with rLH (33.5 versus 25.3, 
p=0.09) (24). 
A meta-analysis by Hill et al. evaluated seven of these trials (45). In that analysis, there was a 
significant increase in implantation (OR 1.36, 95%CI 1.05-1.78) and in clinical pregnancy (OR 
1.37, 95%CI 1.03-1.83) with the use of rLH (45). While the smaller trials have been 
underpowered to detect important clinical outcomes such as implantation and clinical 
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pregnancy, both the largest trial and the meta-analysis suggest a clinical benefit to including 
rLH in the ovarian stimulation of patients with advanced reproductive age.   
It has also been suggested that poor responders will benefit from the addition of LH. A 
common approach to increase LH in poor responders involves the use of the microdose flare 
protocol. This protocol avoids the profound suppression of endogenous LH and FSH in the 
early follicular phase normally achieved with long luteal downregulation protocols. Scott 
and Novat’s initial investigation of the microdose flare found it to have higher peak 
estradiol, more mature follicles and more mature oocytes than a traditional agonist protocol 
(112). While this protocol represents a well-established approach to increasing endogenous 
LH and FSH, randomized controlled trials have been small and inconclusive on whether 
this protocol increases live birth rates (113-116). One RCT did not show any benefit to 
adding either rLH or low-dose rHCG to a microdose flare protocol for poor responders 
(117). A Cochrane review has suggested that poor responders may benefit from the addition 
of rLH (98). In this meta-analysis there was a marked increase in live birth with the use of 
rLH (OR 1.85, 95%CI 1.10-3.11) (98).   
6.1. Summary points 
1. rLH increases implantation and clinical pregnancy in patients 35 years and older 
2. rLH increases live birth in poor responders 
7. Conclusion 
The action of LH is vital to both natural and assisted human reproduction. 
Normogonadotropic patients often have adequate endogenous LH levels, even after GnRH 
analogue pituitary downregulation, to have successful assisted reproduction with FSH 
stimulation alone. However, the addition of LH activity to ovarian stimulation has been 
demonstrated to improve the odds of achieving a live birth. We find the 3-4% improvement 
in live birth with the use of LH activity to be clinically relevant. The inclusion of LH in the 
stimulation of poor responders and women thirty-five and older has been shown to improve 
ART outcomes. Since there are currently no proven methods to determine which patients 
will benefit most from the addition of LH, we recommend clinicians consider some form of 
LH activity in the ovarian stimulation of all patients. 
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